LOGIN  |  REGISTER
Viking Therapeutics

PetIQ to Participate in Two Upcoming June Investor Conferences

June 01, 2023 | Last Trade: US$30.98 0.00 0.00

EAGLE, Idaho, June 01, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced members of the management team will participate in two upcoming June investor conferences.

Wednesday, June 7, 2023 -- William Blair 43rd Annual Growth Stock Conference: The presentation is scheduled for 8:00 a.m. Eastern Time.

Tuesday, June 13, 2023 -- Oppenheimer 23rd Annual Consumer Growth & E-Commerce Virtual Conference: The fireside chat is scheduled for 2:15 p.m. Eastern Time.

The conference presentation and fireside chat will be webcasted and can be accessed live or archived over the Internet hosted at the “Investors” section of the Company's website at www.PetIQ.com

About PetIQ

PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The Company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded and distributed medications as well as health and wellness items, which are further supported by its world-class medications manufacturing facility in Omaha, Nebraska and health and wellness manufacturing facility in Springville, Utah. The Company’s national service platform operates in over 2,600 retail partner locations in 41 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.

Investors: This email address is being protected from spambots. You need JavaScript enabled to view it. or 208.513.1513
Media: This email address is being protected from spambots. You need JavaScript enabled to view it. or 407.929.6727

Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page